Edotreotide

From Wikipedia, the free encyclopedia
  (Redirected from Yttrium Y 90-DOTA-tyr3-octreotide)
Jump to: navigation, search
Edotreotide
DOTATOC.png
Names
IUPAC name
2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
Identifiers
204318-14-9 N
Jmol-3D images Image
PubChem 158782
UNII U194AS08HZ YesY
Properties
C65H92N14O18S2
Molar mass 1,421.64 g·mol−1
Except where noted otherwise, data is given for materials in their standard state (at 25 °C (77 °F), 100 kPa)
 N verify (what isYesY/N?)
Infobox references
90Y labelled edotreotide

Edotreotide (USAN, codenamed SMT487, also known as (DOTA0-Phe1-Tyr3)octreotide, or DOTATOC) is a substance which, when bound to various radionuclides, is used in the treatment and diagnosis of certain types of cancer.[1]

It has been the subject of a trial by the National Cancer Institute to determine its effects in young cancer patients (up to 25 years of age) for its ability to locate malignant cancer cells without harming normal cells. Specific cancers being included in the trial include neuroblastoma, childhood brain tumours and gastrointestinal cancer.[2]

See also[edit]

References[edit]

  • Bushnell, D. L.; O'Dorisio, T. M.; O'Dorisio, M. S.; Menda, Y.; Hicks, R. J.; Van Cutsem, E.; Baulieu, J. -L.; Borson-Chazot, F.; Anthony, L.; Benson, A. B.; Oberg, K.; Grossman, A. B.; Connolly, M.; Bouterfa, H.; Li, Y.; Kacena, K. A.; Lafrance, N.; Pauwels, S. A. (2010). "90Y-Edotreotide for Metastatic Carcinoid Refractory to Octreotide". Journal of Clinical Oncology 28 (10): 1652–1659. doi:10.1200/JCO.2009.22.8585. PMID 20194865.  edit